The Venture Codex

Participated · Series A · Jun 2025

Canid offers an integrated platform that automates pediatric vaccine workflows by scanning a vaccine barcode and handling ordering, reporting, billing and compliance. The platform integrates directly with electronic health records and uses AI, software and economies of scale to remove administrative burden and financial risk from practices. Key features include automated logistics, guaranteed payments (no inventory risk), and data-driven patient outreach to improve vaccination completion rates. The company says its solution reduces the 15 weekly hours pediatricians spend on administrative tasks and frees clinicians to focus on patient care. Canid partners with more than 150 pediatricians across 12 states, covers over 300,000 children in patient panels, and has facilitated vaccinations for 121,000 patients. The recent funding will be used to expand the company’s reach among independent pediatric practices across the U.S. Canid provides an end-to-end vaccine workflow automation and management platform that helps practices manage the purchasing, delivery, and record management of vaccines. Its suite of tools offers practices a unified way to engage patients, close care gaps, and reduce provider burnout while delivering higher-quality care. The company’s platform is designed to empower clinicians and drive improvements in public health. Canid raised $1.5M in funding to support growth. The company intends to use the proceeds to expand its geographic presence to ten new U.S. states and to add new tools to manage vaccine patient populations.

Led · Seed · May 2025

Skriber builds an AI-powered medical scribe that captures patient encounters and transforms them into structured clinical notes to help providers reduce administrative time and focus on patient care. The company leverages artificial intelligence to automate clinical documentation and support workflows for healthcare providers. Skriber is led by CEO Hayden Plummer and is based in Salt Lake City, UT. The company raised $1.3M in pre-seed funding to support its growth. Skriber intends to use the funds to scale its platform, invest in further research and development to maintain technological leadership, and expand the team to support sales and customer success efforts. No operating metrics or revenue figures were disclosed in the article.

Participated · Series A · Oct 2024

OncoLens develops oncology-focused AI that extracts key insights from structured and unstructured clinical, molecular, and lab data to identify patients who may have missed treatment-defining diagnostics or therapies in real time. Its collaboration solutions help cancer centers coordinate next steps to ensure timely, multidisciplinary action. The company serves national cancer institutes, academic medical centers, and community-based integrated delivery networks, and also operates internationally after launching in the EMEA region in 2022. With a growing customer base, OncoLens launched the OncoLens Research Network to partner with life‑science commercial, real‑world evidence, and clinical development teams to bring trials and quality-improvement initiatives to its centers. For life‑science partners the company offers access to a diverse, community-focused network to address RWE, diversity and inclusion in trials, and to find patients with rare genomic alterations. The company is led by CEO Anju Mathew and recently raised capital to expand its development efforts. OncoLens provides an integration and collaboration platform to cancer centers that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure it drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Patients can collaborate on treatment plans, track quality for accreditation, and align to care pathways, while health systems can maximize clinical trial participation and referral streams. The company supports creation of centers of excellence that can be leveraged for patient care and provider education. It serves more than 200 cancer centers in the U.S. and has clients in the larger EMEA region. Led by CEO Anju Mathew, OncoLens intends to use the new funds to expand domestic and global footprint into rural communities and low- and middle-income countries to improve capacity, access, and diversity in research. The financial terms of the investment were not disclosed. OncoLens offers a collaborative, HIPAA-compliant tumor board and cancer treatment planning platform that aggregates patient-specific data across EMR, clinical, and genetics systems and provides decision support. Its software includes virtual tumor board technology, workflow automation, survivorship care planning, and clinical decision support to standardize care and improve efficiencies. The platform automatically identifies patient-specific clinical trials at a facility or affiliates and surfaces relevant NCCN/ASCO guidelines and the latest research to support care teams. OncoLens is used or being implemented across several National Cancer Institute-designated cancer centers and large U.S. healthcare delivery networks, and currently serves more than 8,000 cancer care providers. The company has received market recognition with studies showcased in professional journals and conferences. Management says the new funding will accelerate product development and market expansion as it builds on its position in tumor board and treatment-planning software. OncoLens develops tumor board and cancer treatment planning software that consolidates clinical, radiological, and pathological data to streamline multidisciplinary case discussions. Its platform includes an intelligent workflow engine that automates accreditation and quality reporting, facilitates survivorship care planning, and supports more informed clinical decision-making. The company uses proprietary algorithms to reduce clinician workload by matching patients with relevant clinical trials and potential targeted therapies. OncoLens currently serves several large integrated delivery networks (IDNs) and hospitals across the U.S. Led by co-founder and CEO Anju Mathew, the company plans to expand its product capabilities and grow sales and marketing resources using new funding. The recent financing strengthens its position to scale adoption among health systems. OncoLens offers a Software-as-a-Service platform that enables diverse, multispecialty cancer care teams to collaborate on individual patient treatment plans. The platform provides cancer-specific clinical decision support, helps programs track and implement nationally approved quality metrics, and surfaces applicable clinical trials. It consolidates case data and workflows to streamline tumor board management and survivorship care planning, reducing the manual data-aggregation burden described in the article. OncoLens says its solution decreases a cancer center’s workload and saves resources by standardizing discussions and integrating multiple workflows. The company recently closed a $1.35 million seed round to fund strategic growth and product expansion. OncoLens is part of Georgia Tech’s ATDC Accelerate portfolio and has received industry recognitions, including an “Exceptional Research Award” from the Academy of Oncology Nurse Navigators.

Led · Seed · Jan 2024

Shimmer provides adults with ADHD personalized, 1:1 video coaching combined with productivity tools and science-backed learning modules. Users complete intake questions, are matched with one of Shimmer’s 30+ ADHD coaches, and receive weekly sessions plus ongoing exercises and resources. Pricing tiers start at $140/month for weekly 15-minute sessions, $230/month for 30-minute weekly sessions, and $345/month for 45-minute weekly sessions. Since launching in October 2022, Shimmer coaches have held more than 15,000 coaching sessions and the platform is available on iOS, Android and the web. The founders plan to partner with providers, payors, and employers to reduce out-of-pocket costs and to leverage AI to make coaches more efficient without sacrificing authenticity. Shimmer has begun expanding beyond ADHD to support other neurotypes, including autism, and plans corporate training, community support, and broader personal-development offerings. Shimmer is a consumer app that provides coaching for adults with ADHD via a technology-enabled platform. Its core product pairs users with expert ADHD coaches and delivers "bite-sized" weekly 15-minute live video coaching sessions combined with an accountability system in the app. The program and methodology were developed with ADHD experts from NYU and UCSF. Led by CEO Chris Wang, the platform focuses on integrative, mini coaching sessions and progress tracking through the tech platform. In October 2022 Shimmer raised $1.3M in Seed funding and plans to use the proceeds to accelerate growth, expand operations and broaden its business reach. Backers included Y Combinator, Honeystone Ventures, Koa Labs, Megan Hall and Gaingels.

Participated · Series A · Aug 2022

Biotia is a New York, NY health tech company that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Launched from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia operates a SUNY Downstate-affiliated CLIA lab at BioBAT in New York City. Its products include a curated genomics reference library for pathogens, clinical-grade metagenomics assays, and a sequencing-based assay to detect SARS-CoV-2 variants that recently received expanded FDA EUA. The company provides software, data, and lab assays to clinicians, laboratories, and public-health organizations for pathogen detection, characterization, research, and surveillance. Biotia plans to grow its diagnostic offerings and expand capacity for global pathogen research and surveillance while rolling out new algorithms and tools for physicians, researchers, and health systems. Financially, Biotia has raised an oversubscribed $8 million Series A and will use the investment to expand technical capabilities, compliance, and marketing reach. Biotia leverages next-generation DNA sequencing (NGS) and proprietary AI software Chelsea™ to rapidly and accurately identify microorganisms and antimicrobial resistance from clinical and environmental samples. Chelsea can detect known and emerging bacteria, fungi, parasites and viruses from a clinically‑curated and annotated database of over 16,000 microbial species and reports predicted drug resistance and virulence markers. The company has built one of the world’s largest precision metagenomics clinical databases by working with hospitals internationally across sample types including urine, stool, blood, sputum and soft tissue. Biotia plans to launch new CAP/CLIA clinical diagnostic tests in early 2020 and is expanding its offerings from environmental testing and research‑use patient tests to patient diagnostics. The company announced an oversubscribed $2.4M seed raise to further develop and implement its diagnostic testing methods and AI software. The executive team includes Co‑Founder and CEO Dr. Niamh B. O’Hara, Co‑Founder Dr. Christopher E. Mason (Global Director), Co‑Founder and CTO Dr. Rachid Ounit, and Chief Medical Officer Dr. Dorottya Nagy‑Szakal.